CERo Therapeutics Holdings, Inc. (CERO)
CERO moved a median of -1.06% 30 minutes after news, and -1.29% by the close. How CERO actually reacts to news — the realized, point-in-time move the market made, measured across 339 labeled events over the last three years with zero look-ahead.
CERO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.05% | 41% | 335 |
| 30-min | -1.06% | 39% | 337 |
| 60-min | -1.74% | 40% | 338 |
| to close | -1.29% | 39% | 338 |
| Middle 50% of CERO reactions | -5.92% to +1.85% |
|---|---|
| Median reaction (30-min) | -1.06% |
| Measured reactions | 339 |
Half of all CERo Therapeutics Holdings, Inc. news events land between -5.92% and +1.85% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CERO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CERO's baseline. Nothing else.
Recent CERO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K CERO THERAPEUTICS HOLDIN For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -10.88% | -16.67% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -7.69% | |
| Form 10-Q CERO THERAPEUTICS HOLDIN For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +2.73% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.87% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | -8.33% | -7.50% | |
| CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment | Press release | GlobeNewswire | +4.76% | +19.05% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: May 28 | SEC filing · Form 8-K | SEC EDGAR | -10.43% | -31.28% | |
| Form 10-Q CERO THERAPEUTICS HOLDIN For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -6.90% | |
| CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial | Press release | GlobeNewswire | +0.00% | +1.83% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | +0.59% | -7.17% | |
| Form 10-K/A CERO THERAPEUTICS HOLDIN For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -3.14% | |
| Form 10-K CERO THERAPEUTICS HOLDIN For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.45% | -3.23% | |
| CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial | Press release | GlobeNewswire | -5.49% | -3.96% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.67% | |
| Form NT 10-K CERO THERAPEUTICS HOLDIN For: Dec 31 | SEC filing · Form NT | SEC EDGAR | -7.46% | +1.49% | |
| CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial | Press release | GlobeNewswire | +16.33% | +6.67% | |
| CERo Therapeutics Provides Shareholder Update | Press release | GlobeNewswire | +0.00% | -1.29% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.29% | |
| CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors | Press release | GlobeNewswire | +11.84% | +17.11% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | +11.84% | +17.11% | |
| CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient | Press release | GlobeNewswire | +13.33% | +2.22% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Feb 04 | SEC filing · Form 8-K | SEC EDGAR | +13.33% | +2.22% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +13.33% | +2.22% | |
| CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML | Press release | GlobeNewswire | -5.92% | -14.19% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | -1.23% | -5.06% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | -20.00% | -15.70% | |
| CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) | Press release | GlobeNewswire | -6.12% | -13.27% | |
| Form EFFECT CERO THERAPEUTICS HOLDIN | SEC filing · Form EFFECT | SEC EDGAR | +3.74% | +26.44% | |
| Form S-1 CERO THERAPEUTICS HOLDIN | SEC filing · Form S-1 | SEC EDGAR | +11.67% | -3.71% | |
| CERo Therapeutics Announces Trading on OTCQB Market | Press release | GlobeNewswire | +0.00% | -1.24% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Nov 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.24% | |
| Form DEFA14A CERO THERAPEUTICS HOLDIN | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +10.99% | |
| Form DEF 14A CERO THERAPEUTICS HOLDIN For: Dec 19 | SEC filing · Form DEF | SEC EDGAR | -8.63% | +0.47% | |
| Form 10-Q CERO THERAPEUTICS HOLDIN For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +13.21% | +32.08% | |
| Form NT 10-Q CERO THERAPEUTICS HOLDIN For: Sep 30 | SEC filing · Form NT | SEC EDGAR | -12.14% | -24.90% | |
| Form PRE 14A CERO THERAPEUTICS HOLDIN For: Nov 14 | SEC filing · Form PRE | SEC EDGAR | -12.14% | -24.90% | |
| CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing | Press release | GlobeNewswire | -6.26% | -6.42% | |
| CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response | Press release | GlobeNewswire | +1.09% | -14.10% | |
| CERo Therapeutics Announces Listing on OTC Markets | Press release | GlobeNewswire | -6.41% | +58.17% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Oct 29 | SEC filing · Form 8-K | SEC EDGAR | +7.67% | -71.89% | |
| CERo Therapeutics Announces Receipt of Nasdaq Panel Determination | Press release | GlobeNewswire | +7.67% | -71.89% | |
| CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML | Press release | GlobeNewswire | -5.09% | -20.87% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +0.87% | -13.85% | |
| CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 | Press release | GlobeNewswire | -0.35% | -9.41% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +1.24% | -11.65% | |
| CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML | Press release | GlobeNewswire | +4.24% | -3.48% | |
| CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort | Press release | GlobeNewswire | -0.74% | +1.67% | |
| Form 8-K CERO THERAPEUTICS HOLDIN For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -0.88% | -0.55% | |
| CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041 | Press release | GlobeNewswire | +7.33% | +7.49% | |
| CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia | Press release | GlobeNewswire | -2.87% | -20.95% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CERO section they belong to.
Where else CERO is measured.
CERO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is CERo Therapeutics Holdings, Inc.'s median reaction calculated?
Every labeled CERO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 339 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of CERO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CERO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.